119 related articles for article (PubMed ID: 7850775)
1. Increased levels of laminin in ascitic fluid of patients with ovarian cancer.
Byers LJ; Osborne JL; Carson LF; Carter JR; Haney AF; Weinberg JB; Ramakrishnan S
Cancer Lett; 1995 Jan; 88(1):67-72. PubMed ID: 7850775
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
[TBL] [Abstract][Full Text] [Related]
4. Detection of laminin in serum and ascites from patients with epithelial ovarian tumor.
Chu Y; Yang Y; Lin M; Wang Z
J Huazhong Univ Sci Technolog Med Sci; 2002; 22(1):58-9, 68. PubMed ID: 12658785
[TBL] [Abstract][Full Text] [Related]
5. A case of ovarian serous adenocarcinoma suggestive of transformation to an AFP-producing tumor during chemotherapy.
Kataoka A; Nishida T; Sugiyama T; Yakushiji M
J Obstet Gynaecol (Tokyo 1995); 1995 Oct; 21(5):451-9. PubMed ID: 8542468
[TBL] [Abstract][Full Text] [Related]
6. Significance of serum and peritoneal fluid lactate dehydrogenase levels in ovarian cancer.
Boran N; Kayikçioğlu F; Yalvaç S; Tulunay G; Ekinci U; Köse MF
Gynecol Obstet Invest; 2000; 49(4):272-4. PubMed ID: 10828712
[TBL] [Abstract][Full Text] [Related]
7. Oviductal glycoprotein (OVGP1, MUC9): a differentiation-based mucin present in serum of women with ovarian cancer.
Maines-Bandiera S; Woo MM; Borugian M; Molday LL; Hii T; Gilks B; Leung PC; Molday RS; Auersperg N
Int J Gynecol Cancer; 2010 Jan; 20(1):16-22. PubMed ID: 20130498
[TBL] [Abstract][Full Text] [Related]
8. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study.
Topalak O; Saygili U; Soyturk M; Karaca N; Batur Y; Uslu T; Erten O
Gynecol Oncol; 2002 Apr; 85(1):108-13. PubMed ID: 11925128
[TBL] [Abstract][Full Text] [Related]
9. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
10. Peritoneal fluid lactate dehydrogenase in ovarian cancer.
Schneider D; Halperin R; Langer R; Bukovsky I; Herman A
Gynecol Oncol; 1997 Sep; 66(3):399-404. PubMed ID: 9299252
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin is detectable in the ascitic fluid in patients with ovarian tumors.
Stefanovic V; Pakarinen P; Alfthan H; Stenman UH; Leminen A; Pociuviene J; Riska A; Loukovaara M
Int J Gynecol Cancer; 2012 Nov; 22(9):1470-3. PubMed ID: 23027039
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of a Kunitz-type protease inhibitor in ascites fluid from patients with ovarian carcinoma.
Kobayashi H; Hirashima Y; Sun GW; Ohi H; Fujie M; Terao T
Int J Cancer; 2000 Jul; 87(1):44-54. PubMed ID: 10861451
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis and cell proliferation correlated with tumour grade in peritoneal fluids of patients with serous ovarian cancer.
Kalogeraki A; Karvela-Kalogeraki I; Petraki PE; Zois I; Tamiolakis D; Stathopoulos EN
Cytopathology; 2011 Dec; 22(6):383-6. PubMed ID: 20738358
[TBL] [Abstract][Full Text] [Related]
14. [Relationship between interleukin-10 level in ascites of patients with primary ovarian epithelial carcinoma and immune defect in peritoneal cavity].
Zhou JW; Cheng Q; Xie X; Chen HZ; Ye DF; Lu WG
Ai Zheng; 2004 May; 23(5):573-6. PubMed ID: 15142457
[TBL] [Abstract][Full Text] [Related]
15. [Study of apoptosis and Fas expression of peritoneal fluid and peripheral blood T lymphocytes in patients with epithelial ovarian cancer and their relationship with CA125].
Ma YX; Ye F; Chen HZ; Lü WG; Xie X
Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(11):734-9. PubMed ID: 17565840
[TBL] [Abstract][Full Text] [Related]
16. The ascites N-glycome of epithelial ovarian cancer patients.
Biskup K; Braicu EI; Sehouli J; Tauber R; Blanchard V
J Proteomics; 2017 Mar; 157():33-39. PubMed ID: 28188862
[TBL] [Abstract][Full Text] [Related]
17. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Romanini C; Biagini G
Anticancer Res; 1996; 16(4A):2123-7. PubMed ID: 8712754
[TBL] [Abstract][Full Text] [Related]
18. nm23 expression in malignant ascitic effusions of serous ovarian adenocarcinoma.
Simone G; Falco G; Caponio MA; Campobasso C; De Frenza M; Petroni S; Wiesel S; Leone A
Int J Oncol; 2001 Nov; 19(5):885-90. PubMed ID: 11604983
[TBL] [Abstract][Full Text] [Related]
19. Tumor cell‑fibroblast heterotypic aggregates in malignant ascites of patients with ovarian cancer.
Han Q; Huang B; Huang Z; Cai J; Gong L; Zhang Y; Jiang J; Dong W; Wang Z
Int J Mol Med; 2019 Dec; 44(6):2245-2255. PubMed ID: 31638162
[TBL] [Abstract][Full Text] [Related]
20. Different levels of sialyl-Tn antigen expressed on MUC16 in patients with endometriosis and ovarian cancer.
Akita K; Yoshida S; Ikehara Y; Shirakawa S; Toda M; Inoue M; Kitawaki J; Nakanishi H; Narimatsu H; Nakada H
Int J Gynecol Cancer; 2012 May; 22(4):531-8. PubMed ID: 22367369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
